Haiyang Li

Mr. Haiyang Li

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in The American Journal of Pathology
Verified
Journal Article
Open access
GWGuang Wang
Guang Wang
YHYu-Xuan Hu
Yu-Xuan Hu
MHMei-Yao He
Mei-Yao He
YXYun-Hai Xie
Yun-Hai Xie
WSWei Su
Wei Su
Xuesong YangXuesong Yang
Xuesong Yang
Growing evidence shows that the lungs are an unavoidable target organ of diabetic complications. However, the pathological mechanisms of diabetic lung injury are still controversial. This study demonstrated the dysbiosis of the gut and lung microbiome, pulmonary alveolar wall thickening and fibrotic change in streptozotocin (STZ)-induced diabetic mice and antibiotic-induced gut dysbiosis mice compared to controls. In both animal models, the NF-κB signaling pathway was activated in the lungs. Enhanced pulmonary alveolar well thickening and fibrotic change appeared in the lungs of transgenic mice expressing a constitutively active NF-κB mutant compared to wild-type. When lincomycin hydrochloride (LH)-induced gut dysbiosis was ameliorated by fecal microbiota transplant (FMT), enhanced inflammatory response in the intestine, and pulmonary fibrotic change in the lungs were significantly decreased compared to LH-treated mice. Furthermore, the application of FMT and Baicalin could also redress the microbial dysbiosis of the gut and lungs in STZ-induced diabetic mice. Taken together, this study data suggest that multiple as yet undefined factors related to microbial dysbiosis of gut and lungs cause pulmonary fibrogenesis associated with DM through an NF-kB signaling pathway.

Verified
Journal Article
Open access
PDF file
NHNan Hu
Nan Hu
HLHaiyang Li
Haiyang Li
CTChangcheng Tao
Changcheng Tao
TXTing Xiao
Ting Xiao
WRWeiqi Rong
Weiqi Rong
As one of the emerging hallmarks of tumorigenesis and tumor progression, metabolic remodeling is common in the tumor microenvironment. Hepatocellular carcinoma (HCC) is the third leading cause of global tumor-related mortality, causing a series of metabolic alterations in response to nutrient availability and consumption to fulfill the demands of biosynthesis and carcinogenesis. Despite the efficacy of immunotherapy in treating HCC, the response rate remains unsatisfactory. Recently, research has focused on metabolic reprogramming and its effects on the immune state of the tumor microenvironment, and immune response rate. In this review, we delineate the metabolic reprogramming observed in HCC and its influence on the tumor immune microenvironment. We discuss strategies aimed at enhancing response rates and overcoming immune resistance through metabolic interventions, focusing on targeting glucose, lipid, or amino acid metabolism, as well as systemic regulation.